Abstract: The invention provides the compound: or a salt thereof, as well as pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt thereof and methods for treating a pathological condition in an animal with the compound or with a pharmaceutically acceptable salt thereof.

Abstract: A method for treating a cancer involving one or more translocations generating an oncogenic fusion transcription factor that requires p300/CBP for activity in an animal, comprising administering a compound of formula (I): or a pharmaceutically acceptable salt thereof to the animal.

Abstract: A device includes a substrate, an electrode, an electrical pad, and a signal line. The signal line is coupled to the substrate and covered by an insulation layer. The signal line is coupled to the electrical pad and the electrode. At least one of the electrode and the signal line includes a diamagnetic material and paramagnetic material, wherein a ratio of the diamagnetic material and the paramagnetic material is selected based on the susceptibility properties of a physiological tissue. The term paramagnetic herein refers to magnetic susceptibility greater than that of the surrounding tissue and diamagnetic refers to magnetic susceptibility lower than that of the tissue.

Abstract: Embodiments herein include a method for detecting a brain condition in a subject. The method can include obtaining a breath sample from the subject and contacting it with a chemical sensor element, where the chemical sensor element includes a plurality of discrete graphene varactors. The method can include sensing and storing capacitance of the discrete graphene varactors to obtain a sample data set and classifying the sample data set into one or more preestablished brain condition classifications. Other embodiments are also included herein.

Abstract: Described herein are small molecule cap-dependent inhibitors, including the compound of the formula: which compounds that can induce the accumulation of the p53 tumor suppressor protein in cancer cells that still express wild-type p53, as well as methods of using those compounds to, among other things, treat neuroblastoma, pediatric glioblastoma multiforme or breast cancer.

Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

Abstract: Systems and methods for the clinical diagnosis of functional bladder states and disorders based upon contractile frequencies and variability. Systems and methods are also provided for the clinical diagnosis of functional bowel states and disorders based upon contractile frequencies and variability.

Abstract: In an embodiment, the present disclosure pertains to methods of inhibiting bacterial growth. Generally, the methods include exposing bacteria to an anti-bacterial compound as disclosed herein. In some embodiments, the exposing occurs in vivo in a subject in order to treat or prevent a bacterial infection. In additional embodiments, the present disclosure pertains to anti-bacterial compounds that are suitable for inhibiting bacterial growth.

Abstract: Described herein are methods of treating RNA virus infections with a therapeutic combination of an antiviral nucleobase compound and a de novo nucleotide biosynthesis inhibitor (DNNBi). An aspect of the invention is a method for the treatment of an RNA virus infection comprising administering a therapeutic combination as a combined formulation or by alternation to a patient, wherein the therapeutic combination comprises therapeutically effective amounts of (i) an antiviral nucleobase or a pharmaceutically acceptable salt thereof, and (ii) a de novo nucleotide biosynthesis inhibitor (DNNBi) or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are anti-OVA-serine proteinase inhibitor (ser-pin) B13 monoclonal antibodies and antigen-binding antibody fragments that selectively and specifically bind to an epitope of serpin B13, compositions con-taining these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. These antibodies and antigen-binding frag-ments thereof are useful for inhibiting serpin B13 and for treating serpin B13-related diseases, e.g., type I diabetes.

Abstract: Materials and methods for gene editing using improved targeted endonucleases and endonuclease systems (e.g., Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) endonuclease systems) are provided herein.

Abstract: A digital-to-analog converter device including a set of components, each component included in the set of components including a number of unit cells, each unit cell being associated with a unit cell size indicating manufacturing specifications of the unit cell is provided by the present disclosure. The digital-to-analog converter device further includes a plurality of switches, each switch included in the plurality of switches being coupled to a component included in the set of components, and an output electrode coupled to the plurality of switches. The digital-to-analog converter device is configured to output an output signal at the output electrode. A first unit cell size associated with a first unit cell included in the set of components is different than a second unit cell size associated with a second unit cell included in the set of components.

Abstract: The exemplary systems, methods, and interfaces may obtain and analyze electrode signals from a plurality of external electrodes. The electrode signals may include at least an anterior set of electrode signals and a posterior set of electrode signals. The anterior and posterior sets of electrode signals may be used to generate, or provide, various metrics of cardiac electrical heterogeneity and various graphical depictions that may be useful in assessing a patient's cardiac functionality.

Abstract: Described herein are methods of recellularizing an organ or tissue matrix.

Abstract: In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine.

Abstract: This document provides oilseed plants (e.g., pennycress plants) having increased levels of one or more saturated fatty acids, increased levels of one or more polyunsaturated fatty acids (PUFAs), altered (e.g., increased or decreased) levels of oleic acid, and/or altered (e.g., increased or decreased) levels of erucic acid. For example, oilseed plants having reduced polypeptide levels and/or reduced polypeptide activity of one or more polypeptides involved in triglyceride synthesis (e.g., diacylglycerol O-acyltransferase 1 (TAG1) can have increased levels of stearic acid, increased levels of one or more PUFAs, altered levels of oleic acid, and/or altered levels of erucic acid. Also provided herein are methods and materials for making and using oilseed plants having increased levels of one or more saturated fatty acids, increased levels of one or more PUFAs, altered levels of oleic acid, and/or altered levels of erucic acid.

Abstract: A cryopreservative composition includes a sugar component with a total concentration of sugar components in the composition of 300 mM or less; a sugar alcohol component, with a total concentration of sugar alcohol components in the composition of 2 M or less; and at least one of a polymer component and albumin, with the proviso that the composition includes less than a cryopreservative amount of dimethyl sulfoxide (DMSO). A method of cryopreserving a cell includes adding a cell to the cryopreservative composition; freezing the composition; storing the frozen composition; thawing the composition; removing the cell from the thawed composition; and culturing the cell under conditions effective for the cell to remain viable. The freezing may include cooling at a rate of 0.1° C./min to 5° C./min. The method may be performed without a washing step after thawing.

Abstract: A digital-to-analog converter device including a set of components, each component included in the set of components including a number of unit cells, each unit cell being associated with a unit cell size indicating manufacturing specifications of the unit cell is provided by the present disclosure. The digital-to-analog converter device further includes a plurality of switches, each switch included in the plurality of switches being coupled to a component included in the set of components, and an output electrode coupled to the plurality of switches. The digital-to-analog converter device is configured to output an output signal at the output electrode. A first unit cell size associated with a first unit cell included in the set of components is different than a second unit cell size associated with a second unit cell included in the set of components.

Abstract: This document provides materials and methods for generating oilseed (e.g., pennycress) plants that having low levels of erucic acid. For example, oilseed plants having reduced expression levels of one or more polypeptides involved in erucic acid metabolism (e.g., fatty acid elongase 1 (FAE1)), as well as materials and methods for making and using oilseed plants having low levels of erucic acid are provided.

Abstract: Block copolymers that include one or more galactose based blocks and one or more cationic blocks; polyplexes including disclosed block copolymers and one or more nucleic acids; and methods of delivering a nucleic acid to a cell which can include delivering a polyplex to the cell.